Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E51.90 EPS (ttm)2.24 Insider Own0.10% Shs Outstand223.00M Perf Week3.74%
Market Cap25.89B Forward P/E16.40 EPS next Y7.08 Insider Trans-3.12% Shs Float222.38M Perf Month5.22%
Income505.40M PEG2.78 EPS next Q1.27 Inst Own97.20% Short Float2.27% Perf Quarter-18.72%
Sales3.47B P/S7.46 EPS this Y162.90% Inst Trans0.06% Short Ratio2.43 Perf Half Y-2.49%
Book/sh40.11 P/B2.89 EPS next Y25.59% ROA3.80% Target Price163.43 Perf Year-3.29%
Cash/sh6.86 P/C16.93 EPS next 5Y18.64% ROE5.70% 52W Range96.18 - 149.34 Perf YTD-5.12%
Dividend- P/FCF29.94 EPS past 5Y14.00% ROI4.10% 52W High-22.26% Beta1.20
Dividend %- Quick Ratio2.50 Sales past 5Y31.50% Gross Margin89.10% 52W Low20.70% ATR3.55
Employees3121 Current Ratio3.00 Sales Q/Q7.50% Oper. Margin18.60% RSI (14)51.70 Volatility2.76% 2.98%
OptionableYes Debt/Eq0.36 EPS Q/Q-16.90% Profit Margin14.60% Rel Volume0.99 Prev Close115.76
ShortableYes LT Debt/Eq0.35 EarningsJan 25 BMO Payout0.00% Avg Volume2.08M Price116.09
Recom1.90 SMA205.31% SMA50-3.87% SMA200-6.96% Volume2,065,270 Change0.29%
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Dec-18-17 04:26PM  Why No Large-Cap Biotech Franchise Is Safe From Threats In 2018 Investor's Business Daily
Dec-12-17 12:42PM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 12, 2017 Capital Cube
Dec-11-17 10:00AM  Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting Business Wire
09:02AM  Analyst Recommendations for Alexion in December 2017 Market Realist
08:41AM  Alexion (ALXN) in Focus: Stock Moves 7.2% Higher Zacks
08:20AM  4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018 Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Gilead Sciences and Alexion Pharmaceuticals ACCESSWIRE
07:32AM  Alexion Pharmaceuticals Strensiq and Kanuma after 3Q17 Market Realist
Dec-10-17 08:43PM  Analysts expect these large-cap U.S. stocks to rise at least 25% in 2018 MarketWatch
Dec-08-17 04:46PM  Elliott Management seeks changes at Alexion - NYT Reuters +7.19%
04:35PM  Elliott Management seeks changes at Alexion - NYT Reuters
04:35PM  A Look at Alexion Pharmaceuticals Soliris after 3Q17 Market Realist
04:25PM  The Hot Stock: Alexion Pharmaceuticals Jumps 7.2% Barrons.com
04:09PM  Why This Biotech Could See 30% Upside In The Second Quarter Investor's Business Daily
03:02PM  How Is Alexion Pharmaceuticals Positioned after 3Q17? Market Realist
01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
11:51AM  Elliott Management Flexes Muscle at Alexion Barrons.com
11:30AM  Boston-bound Alexion sees shares jump amid reported activist pressure American City Business Journals
09:56AM  Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change TheStreet.com
09:40AM  Will Alexion Pharmaceuticals Fight This Activist? 24/7 Wall St.
09:30AM  Stocks to Watch: Amazon, Caterpillar, Alexion, 3M, United Continental, American Outdoor The Wall Street Journal
08:42AM  Stocks making the biggest moves premarket: GM, NKE, ALXN, TRVG & more CNBC
06:37AM  Elliott Management seeks changes at Alexion - NYT (Dec. 7) Reuters
12:51AM  PRESS DIGEST-New York Times business news - Dec 8 Reuters
Dec-07-17 10:19PM  Barron's After Hours: Forescout Jumps, Alexion Gains, Smith & Wesson Parent Slumps Barrons.com
09:26AM  Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers TheStreet.com
06:30AM  Alexion and Halozyme Enter License Agreement for ENHANZE Technology Business Wire
Dec-05-17 01:22PM  Why Alexion Pharmacteuicals Sank 8.9% in November Motley Fool
Dec-04-17 04:54PM  Why Ra Pharmaceuticals, Inc. Got Hammered Today Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Dec-01-17 08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-30-17 10:17AM  Oppenheimer's Top Stock Picks For December Benzinga
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-28-17 10:49AM  Why Omeros Corporation Is the Best Buy in Biotech Right Now Motley Fool
03:53AM  Alexion (ALXN) Down 14.6% Since Earnings Report: Can It Rebound? Zacks
Nov-27-17 11:56AM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 27, 2017 Capital Cube
10:00AM  Alexion to Present at the Citi 2017 Global Healthcare Conference Business Wire
08:20AM  Today's Research Reports on Trending Tickers: Acorda Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-23-17 08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
07:21AM  Has Alexion Pharmaceuticals Inc (ALXN) Improved Earnings Growth In Recent Times? Simply Wall St.
Nov-20-17 08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-15-17 10:47AM  3 Big Stock Charts for Wednesday: Alexion Pharmaceuticals, Inc., Alliance Data Systems Corporation and Snap-on Incorporated InvestorPlace
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-14-17 08:04AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-13-17 03:05PM  Alexion Suffers Quantitative Downgrade, Bearish Charts TheStreet.com
11:37AM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 13, 2017 Capital Cube
Nov-09-17 06:30AM  Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service Business Wire
Nov-08-17 04:05PM  Alexion Appoints Francois Nader, M.D. to its Board of Directors Business Wire
02:41PM  Edited Transcript of ALXN earnings conference call or presentation 26-Oct-17 2:00pm GMT Thomson Reuters StreetEvents
08:20AM  Investor Expectations to Drive Momentum within Carrizo, Coeur, Alexion, Ultra Clean, Alaska Air, and CA Discovering Underlying Factors of Influence GlobeNewswire
07:40AM  Featured Company News - Japanese Patent Office Issued New Patent to Alexion Pharma's Soliris; Extending Patent Protection into 2027 ACCESSWIRE
Nov-07-17 12:18PM  The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October Motley Fool
Nov-06-17 06:30AM  Alexion Receives New Japanese Patent for Soliris® (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio Business Wire
Nov-03-17 01:08PM  Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus Zacks
06:30AM  New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma® (sebelipase alfa) Business Wire
Nov-02-17 11:42AM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 2, 2017 Capital Cube
Nov-01-17 05:43PM  TipRanks: Here are 7 top 'strong buy' stocks from the best-performing analysts CNBC
09:33AM  Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 Capital Cube
09:25AM  New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting Business Wire
Oct-31-17 07:40AM  Featured Company News - Epizyme Presented Data from Phase-1 Trial of Tazemetostat In Children with Relapsed/Refractory INI1-Negative Solid Tumors ACCESSWIRE -6.38%
Oct-30-17 10:00AM  Alexion to Present at the 26th Annual Credit Suisse Healthcare Conference Business Wire
Oct-29-17 03:04PM  3 ETFs to Watch on Biotech Earnings Zacks
Oct-27-17 09:03AM  Analysts Recommendations for Biogen in October 2017 Market Realist
Oct-26-17 05:58PM  Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin TheStreet.com
04:03PM  Celgene Results Called 'Alarming,' As Alexion, Bristol Mixed Investor's Business Daily
02:00PM  How Do Analysts See Alexion Pharmaceuticals Inc (ALXN) Performing Over The Next Year? Simply Wall St.
11:35AM  Celgene Results Called 'Alarming,' As Alexion, Bristol Mixed Investor's Business Daily
08:06AM  Alexion (ALXN) Tops Q3 Earnings, Sales Miss, Shares Up Zacks
08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
07:45AM  Alexion Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:53AM  Alexion beats 3Q profit forecasts Associated Press
06:30AM  Alexion Reports Third Quarter 2017 Results Business Wire
Oct-25-17 09:49AM  Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More Zacks
Oct-24-17 05:18PM  Alexion Rises On 'Best-Case Scenario' FDA Approval For Muscle Disease Investor's Business Daily
01:00PM  Alexion: How Do You Spell Relief? Barrons.com
10:57AM  Is a Beat in Store for Alexion (ALXN) This Earnings Season? Zacks
10:48AM  Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris TheStreet.com
09:35AM  Dow Bolts Higher On Q3 Reports; CAT, Polaris, GM And 3M Rally Investor's Business Daily
09:22AM  Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers TheStreet.com
08:43AM  Is the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock? Zacks
08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
07:15AM  IBD's No. 1 Group Under Pressure; These 6 Key Earnings Loom; S&P 500 Futures Investor's Business Daily
Oct-23-17 08:05PM  FDA Approves Soliris® (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG) Business Wire
Oct-19-17 08:16AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : October 19, 2017 Capital Cube
Oct-18-17 08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Oct-16-17 07:17PM  With An ROE Of 6.11%, Has Alexion Pharmaceuticals Incs (ALXN) Management Done A Good Job? Simply Wall St.
Oct-13-17 10:50PM  ALEXION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) Business Wire
12:01PM  Is It Too Late To Buy Facebook? Investor's Business Daily
Oct-11-17 03:00AM  Alexion Pharmaceuticals Trying To Close In On Key Technical Measure Investor's Business Daily
Oct-10-17 10:00AM  Alexion to Report Third Quarter 2017 Results on Thursday, October 26, 2017 Business Wire
Oct-09-17 08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Oct-06-17 10:50PM  ALEXION INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. - (ALXN) PR Newswire
Oct-05-17 07:39AM  How Strensiq Could Boost Alexions Long-Term Growth Market Realist
Oct-04-17 10:39AM  Gauging Alexions 2018 Growth with Soliris Market Realist
09:11AM  How Is Alexion Pharmaceuticals Positioned after 1H17? Market Realist
07:44AM  Alexion on the Street: Analyst Recommendations in October Market Realist
Oct-03-17 08:14AM  The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO Zacks
Oct-02-17 11:14AM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : October 2, 2017 Capital Cube
09:11AM  3 Biotech and Pharma Stocks with Key FDA Catalysts this October Zacks
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wagner Heidi LSVP, Global Government AffairsOct 02Sale140.0012016,80033,290Oct 04 05:25 PM
Veneman Ann MDirectorSep 05Sale145.81835121,7515,480Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsSep 05Sale146.003,763549,38122,329Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsAug 31Sale142.0061286,90426,092Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsAug 28Sale140.0011,1601,562,40026,704Aug 30 06:13 PM
Veneman Ann MDirectorJul 31Sale137.7470096,4186,315Aug 02 05:18 PM
COUGHLIN CHRISTOPHER JDirectorJun 15Buy117.102,000234,2006,333Jun 16 04:55 PM
BAKER BROS. ADVISORS LPDirectorJun 15Buy117.33656,38777,012,4917,645,906Jun 16 04:04 PM
PARVEN ALVIN SDirectorJun 15Sale116.7883597,5117,568Jun 16 04:54 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy116.321,348,955156,915,4447,317,906Jun 16 04:03 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy118.004,392518,2567,321,850Jun 16 04:04 PM
HANTSON LUDWIGCEOJun 14Buy116.7210,0001,167,20038,725Jun 19 05:21 PM
O'Neill JulieEVP. Global OperationsMar 02Sale133.8065187,10437,864Mar 06 06:03 PM
BELL LEONARDDirectorMar 01Sale132.501,240164,300390,670Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsMar 01Sale132.5015620,67029,010Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerMar 01Sale132.5040453,53039,161Mar 01 07:44 PM
Moriarty John BEVP & General CounselMar 01Sale132.5028237,36544,672Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DMar 01Sale132.5037049,02550,688Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 28Sale131.7033043,46114,884Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 28Sale131.7062582,31338,258Mar 01 07:45 PM
Moriarty John BEVP & General CounselFeb 28Sale131.71910119,85644,954Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 28Sale131.013,783495,61133,860Mar 06 06:03 PM
Carmichael ClareEVP, Chief HR OfficerFeb 28Sale131.71915120,51533,065Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale131.7048063,21629,166Mar 01 07:44 PM
BELL LEONARDDirectorFeb 28Sale131.712,738360,622391,910Mar 01 07:44 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale131.7066487,44931,015Mar 01 07:46 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale131.20910119,39231,679Mar 01 07:46 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale131.2035846,97029,646Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 27Sale131.20860112,83233,980Mar 01 07:44 PM
Moriarty John BEVP & General CounselFeb 27Sale131.2061280,29445,864Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 27Sale131.20719,31530,197Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 27Sale131.20860112,83238,883Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 27Sale131.2026034,11215,214Mar 01 07:45 PM
BELL LEONARDDirectorFeb 09Sale126.8424631,203394,648Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 09Sale126.8416721,18246,476Feb 10 06:05 PM
MACKAY MARTINEVP & Global Head of R&DFeb 09Sale126.8421727,52439,743Feb 10 06:05 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale126.8416721,18234,840Feb 10 06:05 PM
BELL LEONARDDirectorFeb 07Sale128.091,010129,371394,894Feb 08 04:40 PM
Moriarty John BEVP & General CounselFeb 07Sale128.0913517,29246,643Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 07Sale128.0922228,43630,004Feb 08 04:38 PM
Carmichael ClareEVP, Chief HR OfficerFeb 07Sale128.0916621,26335,007Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 06Sale125.703,404427,87235,173Feb 08 04:40 PM
MACKAY MARTINEVP & Global Head of R&DFeb 06Sale125.702,728342,90439,960Feb 08 04:39 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 06Sale125.6916520,73930,268Feb 08 04:39 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 06Sale125.701,045131,35715,474Feb 08 04:39 PM
Wagner Heidi LSVP, Global Government AffairsFeb 06Sale125.691,710214,93530,226Feb 08 04:38 PM
Moriarty John BEVP & General CounselFeb 06Sale125.693,403427,73946,778Feb 08 04:40 PM
O'Neill JulieEVP. Global OperationsFeb 06Sale125.692,795351,30432,589Feb 08 04:40 PM
BELL LEONARDDirectorFeb 06Sale125.697,715969,728395,904Feb 08 04:40 PM
BELL LEONARDDirectorJan 10Option Exercise22.901002,290403,719Jan 13 04:36 PM
BELL LEONARDDirectorJan 10Sale144.9910014,499403,619Jan 13 04:36 PM
BELL LEONARDDirectorJan 09Option Exercise22.904,853111,134408,472Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.9033448,397403,285Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.934,853703,345403,619Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Option Exercise54.2620,1661,094,30426,539Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Option Exercise22.9034,210783,409438,497Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.4066891,783403,619Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.5334,2104,704,730404,287Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale136.862,493341,2023,880Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale138.5420,1662,793,7526,373Jan 09 05:21 PM